Clinical and Pharmacoeconomic Analysis of the Fluconazole Use for the Prophylaxis of Invasive Candidiasis in Very-Low-Birth Weight Infants | CMAC

Clinical and Pharmacoeconomic Analysis of the Fluconazole Use for the Prophylaxis of Invasive Candidiasis in Very-Low-Birth Weight Infants

Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(3):270-279

​ Kolbin A.S., Klimko N.N.
very-low-birth weight infants invasive candidiasis prophylaxis fluconazole pharmacoeconomic analysis
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(3):270-279

Abstract

Very-low-birth weight preterm infants (<1500 g) are at high risk for invasive candidiasis. The prospective randomized controlled clinical trial comparing efficacy of 2 doses of fluconazole (3 and 6 mg/kg) in the prophylaxis of invasive candidiasis in infants (n=104) was performed. Historical control group included 249 infants. The descriptive and pharmacoeconomic analyses (cost of illness analysis; cost-minimization analysis; cost-effectiveness analysis) were used. Results of this study showed that invasive candidiasis developed more frequently in the control group, compared to both fluconazole groups. However, differences between two doses of fluconazole were not significant. Prophylactic use of fluconazole was associated with significantly decreased attributable mortality and was safe. Pharmacoeconomic analysis demonstrated that highest direct costs in the treatment of invasive candidiasis comprises for bed-days (81%), and the lowest one – for the cost of fluconazole (4%). Prophylactic use of fluconazole at dose of 3 mg/kg appeared to be more reasonable in terms of pharmacoeconomics, than the use of 6 mg/kg dose or management of preterm verylow-birth weight infants without antifungal prophylaxis. Therefore we recommend 3 mg/kg dose of fluconazole for the prophylaxis of invasive candidiasis in this patient population.

  • 1. Groll A.H., Walsh T.J. Fungal infections in the pediatric patient. In: Anaissie E.J., McGinnis M.R., Pfaller M.A., editors. Clinical mycology. 1st ed. New York: Churchill Livingstone; 2003. p. 417-42.
  • 2. Самсыгина Г.А., Буслаева Г.Н. Кандидоз новорожденных и детей первого года жизни. Пособие для врачей. М.: Изд-во «Печатный город»; 2004.63 с.
  • 3. Kaufman D., Fairchild K.D. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev 2004; 17:638-80.
  • 4. Stoll B.J., Hansen N., Fanaroff L., et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110:285-91.
  • 5. Kaufman D., Boyle R., Hazen K.C., et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345:1660-6.
  • 6. Kicklighter S.D., Springer S.C., Cox T., et al. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001; 107:293-8.
  • 7. McGuire W., Clerihew L., Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants (Cochrane Review). In: The Cochrane Library, Issue 1 2003. Oxford: Update Software.
  • 8. Bennett J.A. The Consolidated Standards of Reporting Trials (CONSORT): Guidelines for reporting randomized trials. Nurs Res 2005; 54:128-32.
  • 9. Ascioglu S., Rex J.H., Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplant: an international consensus. Clin Infect Dis 2002; 34:7-14.
  • 10. Планирование и проведение клинических исследований лекарственных средств. Под ред. Ю.Б. Белоусова. М.; 2000. с. 223-60.
  • 11. Клинико-экономический анализ. П.А. Воробьев, М.В. Авксентьева, А.С. Юрьев, М.В. Сура. М.: “Ньюдиамед”; 2004. 404 с.
  • 12. Клиническая эпидемиология. Основы доказательной медицины. Флетчер Р., Флетчер С., Вагнер Э. Пер. с англ. М.: Медиа Сфера; 1998. 347 с.
  • 13. Вычислительные методы анализа и распознавания патологических процессов. Гублер Е.В. Л.: Медицина; 1978. 296 с.
  • 14. Altman D.G. Confidence intervals for the number needed to treat. BMJ 1998; 317:1309-12.
  • 15. Bland M., Altman D.G. Statistics Notes: The odds ratio. BMJ 2000; 320:1468.
  • 16. Frattarelli D.A.C., Reed M.D., Giacoia G.P., et al. Antifungals in systemic neonatal candidiasis. Drugs 2004; 64:949-68.
  • 17. Колбин А.С., Шабалов Н.П., Климко Н.Н. Эффективность и безопасность применения системных противогрибковых препаратов у новорожденных. Российский вестник перинатологии и педиатрии 2005; (1):42-8.
  • 18. Колбин А.С., Шабалов Н.П., Климко Н.Н. Кандидоз у новорождённых с очень низкой массой тела при рождении. Клин микробиол антимикроб химиотер 2005; 7(2):189-96.
  • 19. Saiman L., Ludington E., Pfaller M., et al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19:319-24.
  • 20. Колбин А.С., Шабалов Н.П., Любименко В.А., Климко Н.Н. Факторы риска развития кандидемии у недоношенных со сроком гестации менее 32 недель. Clinical Microbiology and Antimicrobial Chemotherapy.2005; 7(1):97-102.
  • 21. Lee B.E., Cheung P., Robinson J.L., et al. Comparative study of mortality and morbidity in premature infants (<1250 g) with candidemia or candidal meningitis. Clin Infect Dis 1998; 27:559-65.
  • 22. Sims M.E., Yoo Y., You H., et al. Prophylactic oral nystatin and fungal infections in very-low-birth weight infants. Am J Perinatol 1988; 5:33-6.
  • 23. Wainer S., Cooper P.A., Funk E., et al. Prophylactic miconazole oral gel for the prevention of neonatal fungal rectal colonization and systemic infection. Pediatr Infect Dis J 1992; 11:713-6.
  • 24. McQuay H.J., Moore R.A. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997; 126:712-20.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared